Helix Biopharma Corp.
HBP.TO
TSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 222.09% | 215.75% | 200.14% | 206.58% | 7.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.53% | 73.12% | 58.00% | 43.77% | 14.14% |
| Operating Income | -54.53% | -73.12% | -58.00% | -43.77% | -14.14% |
| Income Before Tax | -51.20% | -70.50% | -55.52% | -44.95% | -9.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.20% | -70.50% | -55.52% | -44.95% | -9.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.20% | -70.50% | -55.52% | -44.95% | -9.74% |
| EBIT | -54.53% | -73.12% | -58.00% | -43.77% | -14.14% |
| EBITDA | -54.72% | -73.32% | -58.13% | -43.85% | -14.12% |
| EPS Basic | -21.99% | -40.99% | -29.84% | -17.39% | 3.69% |
| Normalized Basic EPS | -22.01% | -41.28% | -29.81% | -17.45% | -7.52% |
| EPS Diluted | -41.24% | -61.54% | -29.84% | -17.39% | 3.69% |
| Normalized Diluted EPS | -22.01% | -41.28% | -29.81% | -17.45% | -7.52% |
| Average Basic Shares Outstanding | 22.20% | 17.83% | 14.40% | 15.98% | 12.93% |
| Average Diluted Shares Outstanding | 22.20% | 17.83% | 14.40% | 15.98% | 12.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |